Longitudinal Circulating Tumor DNA–Guided Resistance Analysis During Second-Line Osimertinib Treatment

Longitudinal Circulating Tumor DNA–Guided Resistance Analysis During Second-Line Osimertinib Treatment

Introduction: In osimertinib-treated EGFR mutation (EGFRm)–positive NSCLC, resistance inevitably occurs. Early resistance mechanism (RM) detection by circulating tumor DNA (ctDNA) in plasma and consecutive targeted treatment may delay progressive disease (PD). In this multicenter prospective study,...

Full description

Saved in:
Bibliographic Details
Main Authors: J.W. Tijmen van der Wel, MD, Merel Jebbink, MD, Vincent van der Noort, PhD, Ferry Lalezari, MD, PhD, Daan van den Broek, PhD, Gerrina Ruiter, MD, PhD, Jacobus A. Burgers, MD, PhD, Paul Baas, MD, PhD, Anne S.R. van Lindert, MD, Eva E. van der Wall, MD, Lisanne E.A. Kastelijn, MD, PhD, Marrit Vermeulen, BSc, Linda J.W. Bosch, PhD, Kim Monkhorst, MD, PhD, Mirjam C. Boelens, PhD, Egbert F. Smit, MD, PhD, Adrianus J. de Langen, MD, PhD
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:JTO Clinical and Research Reports
Subjects:
EGFR
NSCLC
Osimertinib
Resistance
ctDNA
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364325000700
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items